Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 16/20 | 0.55 |
| ▸ | ALOX5AP | P20292 | 12/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | USP7 | Q93009 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543470 | 0.85 | MAP4K4 (0.59) | MAP4K4USP7CHEK2MKNK1 | |
| SCHEMBL16973171 | 0.82 | USP7 (0.48) | FEN1ALOX5APMAP4K4USP7 | |
| SCHEMBL625444 | 0.80 | MAP4K4 (0.57) | FEN1ALOX5APMAP4K4MKNK1 | |
| SCHEMBL29973001 | 0.79 | MAP4K4 (0.56) | MAP4K4USP7CHEK2MKNK1 | |
| SCHEMBL4470993 | 0.78 | CHEK2 (0.56) | MAP4K4USP7CHEK2 | |
| SCHEMBL1665775 | 0.76 | USP7 (0.53) | MAP4K4USP7CHEK2MKNK1 | |
| SCHEMBL19393955 | 0.75 | TAAR1 (0.58) | FEN1ALOX5AP | |
| SCHEMBL19824470 | 0.75 | TAAR1 (0.58) | FEN1ALOX5AP | |
| SCHEMBL19308531 | 0.74 | FEN1 (0.50) | FEN1ALOX5AP | |
| SCHEMBL19400433 | 0.74 | MEN1 (0.50) | FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939661-B2 | Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | SSTR5, SSTR3, NPY5R | FEN1 4700/4885ALOX5AP 1536/4885MAP4K4 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.